DRUG COMBINATIONS
Drugs body flags side effects of heart, Glaucoma medications
The Indian Pharmacopoeia Commission has issued a drug safety alert regarding amlodipine and acetazolamide, highlighting potential adverse reactions. Healthcare professionals are advised to monitor for adverse drug reactions, while patients should be vigilant for any symptoms. Companies may be required to include warnings in drug packaging.
Zydus Lifesciences gets tentative approval from USFDA for BP lowering drug
Zydus Lifesciences announced on Thursday that it has received tentative approval from the US Food and Drug Administration (USFDA) to market its generic Azilsartan Medoxomil tablets, which are used to treat high blood pressure. The USFDA's tentative approval covers Azilsartan Medoxomil tablets in strengths of 40 mg and 80 mg.
Shifty Shellshock death: Here’s the reason behind ‘Crazy Town’ singer’s demise
On Monday, June 24, it was revealed that Shifty Shellshock died at home at age 49, according to the Los Angeles County Medical Examiner. Shellshock met Crazy Town co-founder Bret Mazer in 1992, and the band later added various members.
US lawmakers questions FDAs drug inspection programme in India and China
Three top American lawmakers have raised concerns about the FDA's foreign drug inspection program in India and China. In a letter to FDA Commissioner Robert Califf, they highlighted inconsistencies in inspection outcomes from January 2014 to April 2024. Some inspectors reported no compliance issues in numerous inspections, while others found issues in almost every inspection. The lawmakers, Cathy McMorris Rodgers, Brett Guthrie, and Morgan Griffith, pointed out these discrepancies and called for an investigation into the skill and thoroughness of FDA inspectors to ensure rigorous and consistent inspections.
Everstone to merge two healthcare companies, list combined firm
Everstone Capital, a Pan Asia private equity fund, is merging Translumina Therapeutics, a major cardiac stent maker in India, as part of a big-ticket IPO plan.
Customs department warns against new parcel fraud:'Drug was found in your parcel, will inform police'; how to save yourself from this fraud
New parcel scam: The Central Board of Indirect Taxes and Customs (CBIC) has stated that several people complained to them about a fake parcel scam being conducted in the name of customs. In this scam you get a call from a fake officer informing you that cocaine or other drugs have been found in a parcel with your name. Read to know more about this scam and how to stay safe.
- Go To Page 1
Sun Pharma, Cipla enter licensing agreement with Takeda to market novel gastrointestinal drug in India
Sun Pharma and Cipla have entered a licensing deal with Takeda Pharmaceutical to commercialize Vonoprazan tablets in India. This novel drug, used to treat Gastroesophageal Reflux Disease (GERD) and related acid disorders, will be marketed by Sun Pharma as Voltapraz and by Cipla under their own brands.
Sun Pharma inks pact with Takeda to introduce gastrointestinal drug in India
Sun Pharmaceutical Industries announced a licensing deal with Takeda Pharmaceutical to market Vonoprazan, a novel gastrointestinal drug, in India. The agreement allows Sun Pharma to commercialize 10 mg and 20 mg tablets of Vonoprazan, an innovative treatment for acid peptic disorders, under a non-exclusive patent license.
Look-alike, sounding similar drugs likely to face strict action
Earlier, in January India's Drug Technical Advisory Board (DTAB), India's apex drug advisory body, deliberated on the issue of same brand name (including look-alike and sound-alike ones) for different category of products and it suggested that to ensure patient safety, the manufacturing and marketing of different drugs with same brand name should "not be allowed."
GSK blood cancer drug nearly halves risk of death in late-stage trial
In the trial of 302 patients with relapsed or difficult-to-treat multiple myeloma, 71% of those who received Blenrep in combination with the steroid dexamethasone and pomalidomide were alive without their disease worsening at the end of a year. That compared with progression-free survival (PFS) of 51% of those who were treated with pomalidomide, dexamethasone and bortezomib. Pomalidomide is a generic version of Bristol Myers Squibb's Pomalyst, while bortezomib is the generic of Takeda Pharmaceuticals' Velcade.
Anti-diabetic drugs lead growth in pharmaceuticals market
The pharmaceuticals market in India is witnessing significant growth, with anti-diabetic drugs leading the way with over ₹155 crore in value growth among new brands launched in the past year. The respiratory segment and vitamin/mineral/nutrient segment followed closely behind. The anti-diabetes market has grown rapidly in the last five years, driven by factors like the increasing number of patients and the launch of new drug combinations. The pharmaceutical market rebounded in April 2024, with chronic segments showing faster growth compared to acute segments.
Don’t pop that pill daily: Doctors red-flag proton pump inhibitors used to treat acid reflux, heartburns
The reason for the popularity of PPIs among doctors and patients is not tough to gauge. With unhealthy lifestyles and dietary habits, acidity is common among Indians. While many brands of PPIs are sold almost over-the-counter, Pan, Pantop, Omez and Rablet fly off the chemist’s shelves. Doctors warn that overuse of these drugs can have a slow and debilitating impact.
Matthew Perry death: Why are LAPD and DEA still investigating the case after eliminating foul play?
Matthew Perry, renowned for his portrayal of Chandler Bing on the beloved TV sitcom from 1994 to 2004, passed away at the age of 54. He was discovered unconscious in a swimming pool at his Los Angeles residence in October 2023.
Sun Pharma to pursue M&A, licensing to expand speciality business
Sun Pharma, India's leading pharmaceutical company, plans to pursue licensing and acquisitions as part of its strategy to grow its specialty business, according to a senior executive of the company. The executive noted that in recent years, Sun Pharma has been actively working on building a portfolio of products internally. Moving forward, the company intends to adopt a dual approach, combining both mergers and acquisitions with in-house product development.
Eris Lifesciences Q4 Results: Net profit jumps over 29% to Rs 80 crore
The Ahmedabad-based drug maker reported a net profit of Rs 61.5 crore during the corresponding quarter of the previous year. Revenue of Q4FY 24 grew by 37% YoY to Rs 551 crore. The net debt on March 31 stood at Rs 2700 crore.
India's drug regulator cracks down on antibiotic misuse, seeks list of licensed combinations
India's drug regulator has directed state counterparts to provide a list of antibiotic combinations licensed for manufacturing and marketing within two weeks to combat misuse. This move follows recommendations from an expert sub-committee under the Drugs Technical Authority Board (DTAB) to regulate antibiotic use. The regulator seeks to ban inappropriate combinations and monitor unapproved antibiotics in the market. A sub-committee was formed to examine this issue, leading to the recent directive to state drug regulators and port officers.
Sanofi introduces diabetes drug Soliqua in India
Sanofi India has launched its diabetes drug Soliqua in India, a once-daily injectable combination drug containing insulin and GLP-1 receptor agonist lixisenatide. The medication is available at a therapy cost of Rs 1,850 per pen and is indicated for adults with obesity and type 2 diabetes to improve glycemic control.
ED teams up with US officials, raids drug dealer's home
The US authorities had been conducting an investigation into the alleged involvement of Parvinder Singh and Banmeet Singh, both hailing from Haldwani. The investigation focuses on their alleged involvement in operating an international drug trafficking group, known as 'The Singh Organization', said people in the know.
Doctors combine a pig kidney transplant and a heart device in a bid to extend woman's life
Lisa Pisano's combination of heart and kidney failure left her too sick to qualify for a traditional transplant, and out of options. Then doctors at NYU Langone Health devised a novel one-two punch: Implant a mechanical pump to keep her heart beating and days later transplant a kidney from a genetically modified pig.
Breaking Bad ft. Greater Noida: Why are foreigners coming to UP for setting up meth labs?
Police in Greater Noida uncovered three methamphetamine labs run by foreigners in rented properties over the past year, seizing over 100 kilograms of narcotics worth hundreds of crores. A recent raid resulted in the arrest of four Nigerians and seizure of Rs 100 crore worth of MDMA. Law enforcement also seized 75 kilograms of MDMA in interconnected raids the previous year.
Biocon partners Biomm to commercialise diabetes drug in Brazil
Biocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop, manufacture, and supply the drug, while Biomm will obtain regulatory approval and commercialization in Brazil. Biomm focuses on developing, manufacturing, and commercialising complex biotech and biosimilar drug products.
Alembic Pharma gets tentative USFDA nod for breast cancer drug
The medicine is indicated for the treatment of adult patients with a certain type of advanced or metastatic breast cancer in a combination of drug therapy.
AAP-Cong combine will win all 10 LS seats in Haryana: State AAP chief Sushil Gupta
AAP-Congress combine aims to win all Lok Sabha seats in Haryana. They promise good governance and plan to address issues like unemployment and BJP's targeting of opposition leaders.
Zenith Drugs shares list at 39% premium over IPO price
Zenith Drugs, which was entirely a fresh equity issue of 51.48 lakh shares, received a healthy response from investors. The issue was subscribed 179 times, driven by strong interest across categories. The net proceeds will be used for the purchase of machinery and setting up a new plant, existing manufacturing block upgradation, working capital requirements, and general corporate purposes.
Central drug regulator cracks down on FDCs
In 2012, a parliamentary standing committee of the health ministry had observed in its report that some of the state licensing authorities issued manufacturing licences for a large number of FDCs without prior clearance from the central drug authority, resulting in the availability of several FDCs which were not tested for safety and efficacy.
Centre bans anti-cold fixed drug combination for under-four children
In a letter dated December 18, the drug regulator said that FDC (fixed-dose combination) chlorpheniramine maleate and phenylephrine should not be given to children aged under four. It also said that the firms manufacturing it should carry a warning in this regard on the medicine label and package insert. The decision was taken after a review by a sub-committee of experts.
Govt bans anti-cold fixed drug combination for under-four children
The matter was deliberated in the Subject Expert Committee (SEC- Pulmonary) meeting held on June 6. "The committee recommended that the FDC should not be used in children below four years of age and accordingly the firms should mention warnings in this regard on label and package insert. The recommendation of the SEC has been considered by this office," the letter stated.
Akums gets DCGI nod for triple combination diabetes medication
Akums Drugs and Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) for a triple combination diabetes medication. The drug combines Sitagliptin 100, Pioglitazone 15, and Metformin 1000/500 to provide better treatment without the need for multiple drugs.
Lens on fixed-dose combination drugs containing vitamins, minerals
A committee had been set up under the chairmanship of CK Kokate, former vice-chancellor of KLE University, Belgaum, to review the safety, efficacy and therapeutic justification of these drugs. The Drugs Technical Advisory Board (DTAB), India's top technical board on drugs, has now asked the panel for a report on their evaluation.
Load More
